Detalles de la búsqueda
1.
Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients.
Prostate Cancer Prostatic Dis
; 2024 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38413763
2.
Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy.
Adv Radiat Oncol
; 8(2): 101143, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36845611
3.
Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
Clin Cancer Res
; 13(10): 3058-67, 2007 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17505009
4.
A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer.
Clin Cancer Res
; 13(21): 6486-93, 2007 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17975161
5.
A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.
Pancreas
; 39(6): 913-22, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20182395
6.
A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma.
Clin Cancer Res
; 15(19): 6137-47, 2009 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19789305
7.
Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model.
J Neurooncol
; 87(1): 51-61, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18084721
Resultados
1 -
7
de 7
1
Próxima >
>>